文献速递泌尿生殖与妇科肿瘤放疗

顺铂联合吉西他滨与高适形放疗治疗局部晚期宫颈癌的回顾性研究

Highly conformal combined radiotherapy with cisplatin and gemcitabine for treatment of loco-regionally advanced cervical cancer - a retrospective study.
PubMed 文献 · Radiat Oncol · 2017-12-22

结果显示急性3级腹泻仅1例(6%),无其他3级以上胃肠道或泌尿生殖毒性,常见急性血液学毒性为2级贫血(10例,59%),仅1例3级中性粒细胞减少(6%)。化疗完成率随疗程逐渐下降,辅助化疗有8例(47%)省略。中位随访20个月,6例(35%)复发,其中5例(29%)为全身性疾病。

要点

  • 双药化疗联合高适形放疗的毒性可接受,3级以上胃肠道及泌尿生殖毒性罕见。
  • 化疗完成率随治疗进程下降,吉西他滨从第2周24%省略增至第5周71%省略。
  • 中位随访20个月,35%患者复发,其中29%为全身性复发。

核心结论

  • 顺铂联合吉西他滨与高适形放疗联合应用于局部晚期宫颈癌似乎具有可接受的毒性特征,但需进一步研究确定最佳剂量。

主要发现

  • 急性3级腹泻仅1例(6%),未记录其他3级以上急性或晚期胃肠道或泌尿生殖毒性。
  • 最常见急性血液学毒性为2级贫血,见于10例(59%)患者;3级中性粒细胞减少仅1例(6%)。
  • 化疗省略情况:吉西他滨从第2周至第5周分别有4例(24%)、7例(41%)、8例(47%)、12例(71%)省略;顺铂分别有2例(12%)、3例(18%)、1例(6%)、7例(41%)省略;辅助化疗有8例(47%)省略。
  • 中位随访20个月(范围5-63个月),6例(35%)出现疾病复发,其中5例(29%)为全身性疾病。

关键数值与推荐

  • 选择性盆腔淋巴结体积处方总剂量50.4 Gy。
  • 18FDG-PET/CT阳性淋巴结患者(15例,83.3%)接受追加照射至总剂量62 Gy。
  • 同步化疗剂量:外照射放疗5周期间顺铂40 mg/m2、吉西他滨125 mg/m2;辅助化疗从第10周开始,2周期顺铂50 mg/m2、吉西他滨1000 mg/m2。
  • 近距离放疗:外照射后行3-4次宫腔内图像引导自适应近距离放疗,每次6 Gy。
  • 毒性分级依据CTCAE v4.0。

临床怎么用

  • 对于局部晚期宫颈癌,高适形放疗联合顺铂和吉西他滨双药化疗的毒性可控,但需注意化疗完成率随疗程下降,应密切监测并及时调整剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cisplatin and gemcitabine combined with conventional radiation therapy in the treatment of cervical cancer patients results in a favorable outcome but with excess toxicity. The purpose of this study was to evaluate the toxicity profile of dual chemotherapy and highly conformal external beam radiotherapy with image guided adaptive brachytherapy. METHODS: Seventeen patients with cervical carcinoma FIGO stage IB2-IIIB were treated with curative intent between 2011 and 2015. A total dose of 50.4 Gy was prescribed to the elective pelvic nodal volume. Patients with 18FDG-PET/CT positive lymph nodes (n = 15; 83.3%) received an additional boost to a total dose of 62 Gy. Chemotherapy prescription goals were: concomitant during 5 weeks of external beam radiotherapy (EBRT) 40 mg/m2 cisplatin and 125 mg/m2 gemcitabine, followed by adjuvant chemotherapy from week 10 (2 cycles 50 mg/m2 cisplatin and 1000 mg/m2 gemcitabine). EBRT was followed by 3-4 fractions (6 Gy per fraction) of intrauterine image guided adaptive brachytherapy. Toxicities were graded according to the common terminology criteria for adverse events (CTCAE v 4.0). RESULTS: One (6%) patient developed acute grade 3 diarrhea. We did not record any other acute or late gastrointestinal or urogenital toxicity higher that grade 3. Most common acute hematological toxicity was anemia grade 2 recorded in 10 (59%) patients. There was only one case of grade 3 neutropenia (6%). The number of patients that received the complete chemotherapy regimen was gradually declining during the course of therapy. From week 2 to 5, gemcitabine was omitted in 4 (24%),7 (41%), 8 (47%), and 12 (71%) patients respectively, similarly, cisplatin was omitted in 2 (12%),3 (18%),1 (6%) and 7 (41%) patients respectively. Adjuvant chemotherapy was omitted in 8 patients (47%). During a median follow-up time of 20 months (5 to 63 months) 6 (35%) patients developed disease relapse with 5 (29%) of them in the form of systemic disease. CONCLUSIONS: In contrast to previous findings cisplatin and gemcitabine in combination with highly conformal radiation therapy seems to have an acceptable toxicity profile. Further studies are needed to determine the optimal dosage of the proposed therapy concept.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Cihoric N, Tsikkinis A, Vlaskou Badra E, et al. Highly conformal combined radiotherapy with cisplatin and gemcitabine for treatment of loco-regionally advanced cervical cancer - a retrospective study. Radiat Oncol. 2017. PMID: 29273076. doi:10.1186/s13014-017-0938-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。